New understanding of heart regeneration
Peer-Reviewed Publication
Updates every hour. Last Updated: 31-May-2026 01:15 ET (31-May-2026 05:15 GMT/UTC)
When probes are inserted into the brain for research or clinical purposes, the electrical activity of neurons is recorded. These signals can be used to understand how the brain performs certain computations or even to identify pathological states. However, brains are composed of cell types that perform different roles in computation and are differentially affected by certain psychiatric disorders or drugs. Without a deep understanding of how cell types orchestrate the overall activity patterns, we cannot develop the next generation of therapies.
Researchers from Boston University’s Chobanian & Avedisian School of Medicine, College of Arts & Sciences, College of Engineering and Faculty of Computing & Data Sciences have developed a tool called PhysMAP to separate the “voices” of individual cell types within a crowd of electrical noise by combining several complementary features of each type's electrical signature. This machine learning algorithm could open up the study of how cell types shape both the healthy computations and the pathological states that electrical recordings have long been able to detect but never fully understood.
Target identification is a critical and challenging step in drug discovery, with only a small fraction of human genes considered druggable and even fewer successfully targeted by approved therapies. Traditionally, this process has been slow and complex, but artificial intelligence (AI) is transforming it into a more systematic, data-driven approach.
A recent review by Insilico Medicine highlights how AI is accelerating target discovery by integrating vast multimodal datasets—including omics data, clinical records, imaging, and scientific literature—to uncover novel disease mechanisms and therapeutic targets.
Advanced machine learning methods, such as supervised and unsupervised learning, graph neural networks, and generative AI models, enable researchers to prioritize targets, simulate biological systems, and generate new hypotheses with greater precision. Platforms like PandaOmics and emerging “virtual biologist” AI agents further enhance this capability by synthesizing complex biological knowledge.
Clinical progress demonstrates the real-world impact of these approaches, with AI-enabled platforms accelerating timelines and contributing to promising therapies, such as the TNIK inhibitor rentosertib for idiopathic pulmonary fibrosis.
Looking ahead, the field is moving toward AI-driven closed-loop systems that integrate computational predictions with automated experimentation, aiming to significantly improve efficiency, success rates, and the delivery of new treatments to patients.